Study Shows Hormone Therapy Boosts Weight Loss Response to Semaglutide in Postmenopausal Women

Postmenopausal women who are struggling with weight loss may find hope in a new study that suggests hormone therapy could enhance the effects of the popular anti-obesity drug semaglutide. The study, published in the journal Menopause, found that postmenopausal women who received hormone therapy alongside semaglutide experienced significantly greater weight loss compared to those who did not receive hormone therapy.

Lead author Maria Daniela Hurtado, MD, of the Mayo Clinic, explained that the data clearly showed a difference in weight loss outcomes between the two groups. Women on hormone therapy lost approximately 30% more weight and showed significantly greater total body weight loss at all time points over 12 months compared to those not on hormone therapy.

The study, which included 106 postmenopausal women who were overweight or obese and treated with semaglutide for at least a year, highlighted the potential benefits of combining hormone therapy with anti-obesity drugs for weight management in menopausal women. The findings suggest that hormone therapy may play a role in enhancing the weight loss response to semaglutide.

Weight gain during menopause is a common concern for many women, with nearly 70% experiencing changes in weight that can increase the risk of cardiometabolic diseases. The study’s results offer new insights into how hormone therapy could potentially help postmenopausal women achieve their weight loss goals.

While the study had limitations, including a small sample size and the possibility of healthy user bias, the findings provide valuable information for healthcare providers and women seeking effective weight loss strategies during menopause. Further research is needed to confirm the results and explore the mechanisms behind the differential weight loss response observed in the study.

Overall, the study highlights the potential benefits of combining hormone therapy with anti-obesity drugs for postmenopausal women struggling with weight management. As demand for anti-obesity drugs continues to rise among menopausal women, these findings could have significant implications for weight loss treatment in this population.